PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer.
Daphne Gschwantler-KaulichYen Y TanEva-Maria FuchsGernot HudelistWolfgang J KöstlerAngelika ReinerCarmen LeserMohamed SalamaJohannes AttemsChristine DeutschmannChristoph C ZielinskiChristian F SingerPublished in: PloS one (2017)
In Her-2-positive metastatic breast cancers, PTEN positivity was significantly associated with progressive disease, but not with PFS or OS.